According to a market report by Lucintel, the future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 from $2.1 billion in 2024,at a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.
A more than 150-page report to understand trends, opportunity and forecast in radiopharmaceutical theranostics market to 2030 by product type (alpha emitters, beta emitters, and PET tracers), source (nuclear reactors and cyclotrons), indication (oncology, cardiology, neurology, and others), end use (hospitals, diagnostic imaging centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the product type category, PET tracer is expected to witness the highest growth over the forecast period.
Within the end use category, hospitals will remain the largest segment due to availability of technologically advanced systems and rising number of hospitals.
In terms of region, North America is expected to witness the highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.
Download sample by clicking on radiopharmaceutical theranostics market
Bayer, GE Healthcare Technologies, Curium, Lantheus Medical Imaging, Telix Pharmaceuticals, Cardinal Health, Advanced Accelerator Applications, Jubilant Radiopharma, Theragnostics, Nuview Life Sciences are the major suppliers in the radiopharmaceutical theranostics market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]To get access of more than 1000 reports at fraction of cost visit Lucintel'sAnalytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market &unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Conductive Polymer Coating Market
Titanate Praseodymium Target Market
Comments on “Lucintel Forecasts the Global Radiopharmaceutical Theranostics Market to Reach $3.9 billion by 2030”